{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:53Z","timestamp":1782992213872,"version":"3.54.5"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Buprenorphine remains underused in treating opioid use disorder, despite its effectiveness. During the onset of the COVID-19 pandemic, the US government implemented prescribing flexibilities to support continued access.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether buprenorphine-involved overdose deaths changed after implementing these policy changes and highlight characteristics and circumstances of these deaths.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study used data from the State Unintentional Drug Overdose Reporting System (SUDORS) to assess overdose deaths in 46 states and the District of Columbia occurring July 2019 to June 2021. Data were analyzed from March 7, 2022, to June 30, 2022.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Buprenorphine-involved and other opioid-involved overdose deaths were examined. Monthly opioid-involved overdose deaths and the percentage involving buprenorphine were computed to assess trends. Proportions and exact 95% CIs of drug coinvolvement, demographics, and circumstances were calculated by group.<\/jats:p><\/jats:sec>Results<\/jats:title>During July 2019 to June 2021, 32 jurisdictions reported 89\u202f111 total overdose deaths and 74\u202f474 opioid-involved overdose deaths, including 1955 buprenorphine-involved overdose deaths, accounting for 2.2% of all drug overdose deaths and 2.6% of opioid-involved overdose deaths. Median (IQR) age was similar for buprenorphine-involved overdose deaths (41 [34-55] years) and other opioid\u2013involved overdose deaths (40 [31-52] years). A higher proportion of buprenorphine-involved overdose decedents, compared with other opioid\u2013involved decedents, were female (36.1% [95% CI, 34.2%-38.2%] vs 29.1% [95% CI, 28.8%-29.4%]), non-Hispanic White (86.1% [95% CI, 84.6%-87.6%] vs 69.4% [95% CI, 69.1%-69.7%]), and residing in rural areas (20.8% [95% CI, 19.1%-22.5%] vs 11.4% [95% CI, 11.2%-11.7%]). Although monthly opioid-involved overdose deaths increased, the proportion involving buprenorphine fluctuated but did not increase during July 2019 to June 2021. Nearly all (92.7% [95% CI, 91.5%-93.7%]) buprenorphine-involved overdose deaths involved at least 1 other drug; higher proportions involved other prescription medications compared with other opioid-involved overdose deaths (eg, anticonvulsants: 18.6% [95% CI, 17.0%-20.3%] vs 5.4% [95% CI, 5.2%-5.5%]) and a lower proportion involved illicitly manufactured fentanyls (50.2% [95% CI, 48.1%-52.3%] vs 85.3% [95% CI, 85.1%-85.5%]). Buprenorphine decedents were more likely to be receiving mental health treatment than other opioid\u2013involved overdose decedents (31.4% [95% CI, 29.3%-33.5%] vs 13.3% [95% CI, 13.1%-13.6%]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this cross-sectional study suggest that actions to facilitate access to buprenorphine-based treatment for opioid use disorder during the COVID-19 pandemic were not associated with an increased proportion of overdose deaths involving buprenorphine. Efforts are needed to expand more equitable and culturally competent access to and provision of buprenorphine-based treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.51856","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T16:05:10Z","timestamp":1674230710000},"page":"e2251856","source":"Crossref","is-referenced-by-count":41,"title":["Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic"],"prefix":"10.1001","volume":"6","author":[{"given":"Lauren J.","family":"Tanz","sequence":"first","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Davis","sequence":"additional","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson M.","family":"Compton","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant T.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Han","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora D.","family":"Volkow","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"50","key":"zoi221477r1","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls\u2014United States, 2019-2020.","volume":"70","author":"O\u2019Donnell","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi221477r8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: the foundation of recovery.","volume":"31","author":"Bart","year":"2012","journal-title":"J Addict Dis"},{"issue":"8","key":"zoi221477r9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection.","author":"Gowing","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"9358","key":"zoi221477r10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"zoi221477r11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi221477r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"zoi221477r13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am J Public Health"},{"issue":"2","key":"zoi221477r14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence.","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"1","key":"zoi221477r15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: opioid use disorder and COVID-19.","volume":"173","author":"Alexander","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi221477r16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics.","volume":"173","author":"Volkow","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi221477r22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1080\/10826084.2022.2079140","article-title":"Increased attendance during rapid implementation of telehealth for substance use disorders during COVID-19 at the largest public hospital system in the United States.","volume":"57","author":"Avalone","year":"2022","journal-title":"Subst Use Misuse"},{"key":"zoi221477r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108783","article-title":"Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.","volume":"225","author":"Jones","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi221477r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100055","article-title":"Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program.","volume":"3","author":"Ward","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"5","key":"zoi221477r26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/add.v117.5","article-title":"Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018-December 2019.","volume":"117","author":"O\u2019Donnell","year":"2022","journal-title":"Addiction"},{"issue":"166","key":"zoi221477r27","first-page":"1","article-title":"2013 NCHS urban-rural classification scheme for counties.","author":"Ingram","year":"2014","journal-title":"Vital Health Stat 2"},{"issue":"9","key":"zoi221477r28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs.","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi221477r30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41380-020-00949-3","article-title":"Polysubstance use in the U.S. opioid crisis.","volume":"26","author":"Compton","year":"2021","journal-title":"Mol Psychiatry"},{"key":"zoi221477r32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: motivations for use, practices of diversion, and experiences of stigma.","volume":"70","author":"Allen","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"zoi221477r33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: motives for abuse, misuse, and diversion.","volume":"104","author":"Chilcoat","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi221477r34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment.","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi221477r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.14765","article-title":"Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic.","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"29","key":"zoi221477r36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","article-title":"Vital Signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics\u201425 states and the District of Columbia, 2019-2020.","volume":"71","author":"Kariisa","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi221477r37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.2022.12240","article-title":"Increases in disparities in US drug overdose deaths by race and ethnicity: opportunities for clinicians and health systems.","volume":"328","author":"Kariisa","year":"2022","journal-title":"JAMA"},{"key":"zoi221477r3","volume-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2022"},{"key":"zoi221477r5","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"zoi221477r6","volume-title":"Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP","author":"Substance Abuse and Mental Health Services Administration","year":"2015"},{"key":"zoi221477r7"},{"key":"zoi221477r20"},{"key":"zoi221477r2","unstructured":"US Drug Enforcement Administration, Drug Enforcement Administration Diversion Control Division. NFLIS-Drug 2020 annual report. Accessed July 18, 2022. https:\/\/www.nflis.deadiversion.usdoj.gov\/nflisdata\/docs\/NFLISDrug2020AnnualReport.pdf"},{"key":"zoi221477r4","unstructured":"Haffajee? RL, Sherry? TB, Dubenitz? JM, . US Department of Health and Human Services overdose prevention strategy. Accessed July 18, 2022. https:\/\/aspe.hhs.gov\/reports\/overdose-prevention-strategy"},{"key":"zoi221477r17","unstructured":"Federal Emergency Management Agency. Nationwide emergency declaration for COVID-19. 2020. Accessed: July 18, 2022. https:\/\/www.fema.gov\/disaster\/coronavirus\/disaster-declarations"},{"key":"zoi221477r18","unstructured":"US Department of Health and Human Services. Public health emergency determination for 2019 novel coronavirus. Accessed: July 18, 2022. https:\/\/www.phe.gov\/emergency\/news\/healthactions\/phe\/Pages\/2019-nCoV.aspx"},{"key":"zoi221477r19","unstructured":"Drug Enforcement Administration. Flexibility during the nationwide public health emergency to prescribe buprenorphine. Accessed July 18, 2022. https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf"},{"key":"zoi221477r21","unstructured":"Centers for Medicare and Medicaid Services. Medicare payment policies during COVID-19. Accessed July 18, 2022. https:\/\/telehealth.hhs.gov\/providers\/billing-and-reimbursement\/medicare-payment-policies-during-covid-19\/"},{"key":"zoi221477r25","unstructured":"Centers for Disease Control and Prevention. CDC\u2019s State Unintentional Drug Overdose Reporting System (SUDORS). Accessed July 18, 2022. https:\/\/www.cdc.gov\/drugoverdose\/fatal\/sudors.html"},{"key":"zoi221477r29","unstructured":"US Department of Health and Human Services. Agency priority goal: behavioral health. Accessed July 19, 2022. https:\/\/assets.performance.gov\/APG\/files\/2022\/june\/FY2022_June_HHS_Progress_Behavioral_Health.pdf"},{"key":"zoi221477r31","unstructured":"National Harm Reduction Coalition. Opioid overdose basics: overdose risks and prevention. Accessed July 18, 2022. https:\/\/harmreduction.org\/issues\/overdose-prevention\/overview\/overdose-basics\/opioid-od-risks-prevention\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2800689\/tanz_2023_oi_221477_1673544642.2046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T16:05:20Z","timestamp":1674230720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2800689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.51856","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}